Q3 Earnings Estimate for Organovo Issued By Zacks Small Cap

Organovo Holdings, Inc. (NASDAQ:ONVO) – Stock analysts at Zacks Small Cap upped their Q3 2025 EPS estimates for Organovo in a research report issued to clients and investors on Monday, November 11th. Zacks Small Cap analyst B. Sorensen now anticipates that the medical research company will earn ($0.21) per share for the quarter, up from their previous forecast of ($0.25). The consensus estimate for Organovo’s current full-year earnings is ($0.77) per share. Zacks Small Cap also issued estimates for Organovo’s Q4 2025 earnings at ($0.29) EPS, FY2025 earnings at ($0.77) EPS, Q1 2026 earnings at ($0.19) EPS, Q2 2026 earnings at ($0.19) EPS, Q4 2026 earnings at ($0.17) EPS, FY2026 earnings at ($0.75) EPS and FY2027 earnings at ($0.75) EPS.

Separately, StockNews.com assumed coverage on shares of Organovo in a report on Monday. They set a “sell” rating for the company.

Organovo Price Performance

NASDAQ ONVO opened at $0.36 on Wednesday. The stock has a market capitalization of $5.53 million, a P/E ratio of -0.33 and a beta of 0.62. Organovo has a 52-week low of $0.35 and a 52-week high of $1.74. The firm has a 50-day moving average price of $0.47 and a 200 day moving average price of $0.67.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Organovo stock. Armistice Capital LLC bought a new position in shares of Organovo Holdings, Inc. (NASDAQ:ONVO) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 929,000 shares of the medical research company’s stock, valued at approximately $708,000. Armistice Capital LLC owned 6.46% of Organovo at the end of the most recent quarter. Hedge funds and other institutional investors own 8.23% of the company’s stock.

About Organovo

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.